Royal Fund Management’s Arbutus Biopharma ABUS Stock Holding History

Royal Fund Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-800	Closed	-$2K	–	449
2017 Q2	$2K	Buy	+800	New	+$2.75K	﹤0.01%	369

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Royal Fund Management's ABUS Position: Q3 2017 in Review

Royal Fund Management sold out of Arbutus Biopharma (ABUS) in Q3 2017, closing a stake of 800 shares — an estimated $2K sold.

Royal Fund Management first reported a position in ABUS in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 53 funds tracked by Wall St. Rank hold ABUS as of Q3 2017.

Royal Fund Management reported no remaining Arbutus Biopharma position as of Q3 2017 after selling out during the quarter.
Royal Fund Management sold 800 Arbutus Biopharma shares in Q3 2017, an estimated $2K.
Royal Fund Management first reported a position in Arbutus Biopharma in Q2 2017 and held it in 1 quarter.
Royal Fund Management's Arbutus Biopharma position peaked at $2K in Q2 2017.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2017.

Based on Royal Fund Management's 13F filing for Q3 2017, filed 7 May 2020.